Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 9/2013

01-09-2013 | Short Communication

Successful childbearing in two women with rheumatoid arthritis and a history of miscarriage after etanercept treatment

Authors: Ikumi Natsumi, Yoshihiro Matsukawa, Kohji Miyagawa, Hitomi Kodaira, Toshitake Tanaka, Akira Horikoshi, Jin Takeuchi, Masami Takei, Mamoru Maejima, Jun Akimoto

Published in: Rheumatology International | Issue 9/2013

Login to get access

Abstract

Two women with rheumatoid arthritis who had experienced miscarriages became pregnant while they were under etanercept treatment. One stopped etanercept after 3 weeks with increased doses of prednisolone, and the other restarted etanercept at a half doses 3 months later. They delivered a healthy baby at full term, and no problems in both expecting mothers and babies were observed. The use of etanercept in patients with rheumatoid arthritis seemed safe for pregnant mothers and their fetuses.
Literature
1.
Katz JA, Antoni C, Keenan GF, Smith DE, Jacob SJ, Lichtenstein GR (2004) Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol 99:2385–2392PubMedCrossRef
2.
Verstappen SMM, King Y, Watson KD, Symmons DPM, Hyrich KL (2011) Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70:823–826PubMedCrossRef
3.
Sills ES, Perloe M, Tucker MJ, Kaplan CR, Palemo GD (2001) Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anti-cytokine treatment for rheumatoid arthritis. Am J Reprod Immunol 46:366–368PubMedCrossRef
4.
Murashima A (2008) Treatment of patients with rheumatoid arthritis who desire to become pregnant–successful pregnancy in three cases treated with etanercept. Nippon Rinsho 66:2215–2220 (Japanese with English abstract)PubMed
5.
Chakravarty EF, Sanchez-Yamamoto D, Bush TM (2003) The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcome. J Rheumatol 30:241–246PubMed
6.
Sinha A, Patient C (2006) Rheumatoid arthritis in pregnancy: successful outcome with anti-TNF agent (Etanercept). J Obstet Gynecol 26:689–691CrossRef
7.
Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L (2007) Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-α therapy. Rheumatology 46:695–698PubMedCrossRef
8.
Otermin I, Elizondo G, Zabaleta J, Amigot A (2007) Etanercept and pregnancy. Am Sist Sanit Navar 30:491–493
9.
Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K (2009) Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis 68:1793–1794PubMedCrossRef
10.
Berthelot J, De Bandt M, Goupille P, Solau-Gervais E, Liote F, Goeb V et al (2009) Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76:28–34PubMedCrossRef
11.
Umeda N, Ito S, Hayashi T, Goto D, Matsumoto I, Sumida T (2010) A patient with rheumatoid arthritis who had a normal delivery under etanercept treatment. Intern Med 49:187–189PubMedCrossRef
12.
Rump JA, Schonborn H (2010) Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment. Z Rheumatol 69:902–909CrossRef
13.
Mahadevan U, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG (2005) Intentional infliximab use during pregnancy for induction or maintenance remission in Crohn’s disease. Aliment Pharmacol Ther 21:733–738PubMedCrossRef
14.
de Man YA, Hazes MW, vander Heide H, Willmsen SP, de Groot CJM, Steeger AP et al (2009) Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight. Arthrit Rheum 60:3196–3206CrossRef
15.
Carter JD, Ladhani A, Ricca LA, Valeriano J, Vasey FB (2009) A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 36:635–641PubMedCrossRef
16.
Koren G, Inoue M (2009) Do tumor necrosis factor inhibitors cause malformations in humans? J Rheumatol 36:465–466PubMedCrossRef
Metadata
Title
Successful childbearing in two women with rheumatoid arthritis and a history of miscarriage after etanercept treatment
Authors
Ikumi Natsumi
Yoshihiro Matsukawa
Kohji Miyagawa
Hitomi Kodaira
Toshitake Tanaka
Akira Horikoshi
Jin Takeuchi
Masami Takei
Mamoru Maejima
Jun Akimoto
Publication date
01-09-2013
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 9/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2433-1

Other articles of this Issue 9/2013

Rheumatology International 9/2013 Go to the issue

Short Communication

l-Carnitine enhances extracellular matrix synthesis in human primary chondrocytes

Original Article

Core set of recommendations for patients with ankylosing spondylitis concerning behaviour and environmental adaptations

Short Communication

Giving rheumatology patients online home access to their electronic medical record (EMR): advantages, drawbacks and preconditions according to care providers

Original Article

Preliminary investigation of absent nociceptive flexion reflex responses among more symptomatic women with fibromyalgia syndrome

Short Communication

Camptocormia as a clinical manifestation of polymyositis/systemic sclerosis overlap myositis associated with anti-Ku

Original Article

T cell responses to citrullinated self-peptides in patients with rheumatoid arthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits